Posted by Michael Wonder on 29 Aug 2023
Roche’s Tecentriq becomes the first subcutaneous anti-PD-(L)1 cancer immunotherapy available to patients in Great Britain, reducing treatment time to just minutes
29 August 2023 - Tecentriq subcutaneous is now approved in Great Britain for all indications of intravenous Tecentriq, including certain types of lung, bladder, breast and liver cancer, offering a faster, more convenient option to receive treatment.
Roche announced today that Tecentriq SC (atezolizumab) has been approved by the Medicines and Healthcare products Regulatory Agency in Great Britain.
